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ABSTRACT 
Cancer claims hundreds of thousands of lives every year in US alone. 
Finding ways for early detection of cancer onset is crucial for better management 
and treatment of cancer. Thus, biomarkers especially protein biomarkers, being 
the functional units which reflect dynamic physiological changes, need to be 
discovered. Though important, there are only a few approved protein cancer 
biomarkers till date.  To accelerate this process, fast, comprehensive and 
affordable assays are required which can be applied to large population studies.  
For this, these assays should be able to comprehensively characterize and explore 
the molecular diversity of nominally “single” proteins across populations. This 
information is usually unavailable with commonly used immunoassays such as 
ELISA (enzyme linked immunosorbent assay) which either ignore protein 
microheterogeneity, or are confounded by it. To this end, mass spectrometric 
immuno assays (MSIA) for three different human plasma proteins have been 
developed. These proteins viz. IGF-1, hemopexin and tetranectin have been found 
in reported literature to show correlations with many diseases along with several 
carcinomas. Developed assays were used to extract entire proteins from plasma 
samples and subsequently analyzed on mass spectrometric platforms. Matrix 
assisted laser desorption ionization (MALDI) and electrospray ionization (ESI) 
mass spectrometric techniques where used due to their availability and suitability 
for the analysis. This resulted in visibility of different structural forms of these 
proteins showing their structural micro-heterogeneity which is invisible to 
commonly used immunoassays. These assays are fast, comprehensive and can be 
applied in large sample studies to analyze proteins for biomarker discovery.   
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Chapter 1 
INTRODUCTION 
1.1 General overview: 
Biomarker discovery and characterization is emerging as a useful tool in early 
diagnosis and subsequent treatment of many diseases. These biomarkers include 
both genetic and proteomic markers. Genetic markers are mainly DNA or RNA 
based markers. DNA-based markers include Single-Nucleotide Polymorphisms 
(SNPs) which can be used to map disease associated genes, chromosomal 
aberrations (such as the well-known Philadelphia translocation associated with 
chronic myelogenous leukemia), changes in DNA copy number and differential 
promoter-region methylation. RNA-based biomarkers include over or under 
expressed transcripts, and regulatory RNAs (for example, the microRNAs). 
HapMap is an international collaborative project to provide researchers world-
wide, information about these genetic markers [6, 7]. Protein markers include 
cell-surface receptors, tumour antigens such as prostate-specific antigen (PSA) 
and proteins/peptides released by cells into serum, urine, sputum or other body 
fluids. The popular genomics approach, while useful in many ways, has its 
limitations. Firstly, the analysis requires sufficient amount of viable RNA.  
Secondly, techniques commonly applied in genomics provide information about 
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the levels of RNA present but do not indicate protein levels because many events 
occur during translation and post-translational modification.  
Proteins themselves are macromolecules which are long chains of amino acids. 
These amino acid chains are constructed in cells when cellular machinery of the 
ribosomes translates RNA transcripts from DNA in the cell's nucleus. Within a 
given human proteome, the number of proteins can be as large as 2 million [8]. 
Proteins can be organized in four structural levels viz. primary, secondary, tertiary 
and quaternary. The primary structure refers to the sequence of amino acids in the 
polypeptide chain. Local folding of amino acid sequence into α helices and β 
sheets is referred to as the secondary structure of a protein and 3D conformation 
of the entire amino acid sequence is the tertiary structure. Interaction between 
multiple protein subunits folded in 3D gives rise to quaternary structure of a 
protein (Figure 1). Each level of protein structure is essential for the proper 
functioning of the protein molecule. Primary sequence of the amino acid chain 
determines where secondary structures will form, as well as the overall shape of 
the final 3D conformation. The 3D conformation of each small peptide or subunit 
determines the final structure and function of a protein conglomerate. Serving as 
important components of the physiological pathways in cells, proteins play 
critical roles in vital functions of the body such as, catalyzing various biochemical 
reactions as enzymes; acting as messengers, e.g. neurotransmitters; acting as 
control elements that regulate cell reproduction; influencing growth and 
development of various tissues, e.g. growth factors; transporting oxygen in the 
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blood, e.g. hemoglobin; and defending the body against disease, e.g. antibodies. 
When accurately characterized, proteins represent the dynamic state of cells, 
reflecting pathophysiological changes arrising due to certain diseases in a more 
timely and accurate manner than genomic and epigenetic alterations. 
Figure 1: Characterization of protein structure. Courtesy: 
National Human Genome Research Institute 
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1.2 Proteins as biomarkers:  
According to National Institute of health, biomarkers of disease are 
“Characteristics that are objectively measured and evaluated as indicators of 
normal biologic processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention” [9]. In case of proteins these characteristics can 
represent either change in concentration, amino acid sequence, and/or 
posttranslational modifications. Ideally, biomarkers of diseases are blood-based 
molecules that indicate state of the disease, allowing for minimally invasive 
testing. Such analysis not only helps in early diagnosis of a disease but also 
provides a reliable measure to monitor the course of the treatment and help 
doctors tailor their medication type and doses. Over the past decade, due to rapid 
development and improvement of proteomic technologies, hundreds of potential 
protein biomarkers have been identified [10]. But, to be approved as a clinically 
useful biomarker, a protein molecule must meet several conditions. Firstly, in 
order to distinguish normal from diseased samples the biomarker should have 
tissue specific expression. Expression in additional tissues means a high level of 
expression in normal healthy individuals. Secondly, to be effective for early 
diagnosis, the potential biomarker protein must be released into circulation at a 
detectable concentration at an early disease state. Biomarkers not expressed in the 
early stages are useful only for disease staging and monitoring. Thirdly, there 
must be sufficient biomarker released from the diseased tissue to be detectable 
over other highly expressed background proteins and lastly a biomarker should be 
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predictive which means it should have sufficient life in the blood and should also 
be released in proportional amount to the disease progression. 
1.3 Cancer Biomarkers 
According to American Cancer Society Cancer is a group of diseases 
characterized by uncontrolled growth and spread of abnormal cells. If the spread 
is not controlled, it can result in death. Cancer is the second most common cause 
of death in the US, exceeded only by heart disease. It is the cause of one in every 
four deaths in the United States. In 2011 alone, about 571,950 Americans are 
expected to die of cancer which is more than 1,500 people a day [11]. Even on a 
global scale cancer is becoming an alarmingly higher cause of death. Worldwide, 
cancer was estimated to be responsible for 13% of all deaths in 2007 [12]. Given 
these numbers, prevention of cancer is very important for societies on a global 
level. It is predicted that approximately one-third of all cancer cases could be 
prevented if detected at an early enough stage [12]. This means that appropriate 
biomarkers could play a big role in allowing clinicians to detect cancer onset at 
right time and save patient’s lives. Cancer is a complex heterogeneous disease 
which evolves via multiple pathways and is a result of a variety of genetic, 
molecular, and clinical events which are not very well understood even till 
date[13]. Given that there is significant variation in the risk of developing cancer 
and that early detection often results in increased survival, finding biomarkers 
capable of identifying patients at highest risk and detecting tumors in the earliest 
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stages of development is a pressing need. In addition, suitable and high 
throughput techniques to screen a larger population in a cost effective manner is 
required. 
In recent years, the focus of the scientific community on cancer and the rapid 
technological advances in the field of proteomics has led to identification of 
hundreds of potential protein biomarkers for cancer. Even though many potential 
biomarkers have been identified, very few have successfully advanced beyond the 
discovery phase to become clinically useful diagnostic biomarkers. Food and 
Drug Administration (FDA),
 
has only approved less than two dozen cancer 
biomarkers [13]. of which only nine are protein biomarkers identifiable in the 
blood [14]. These protein markers include cancer antigen-125 (CA-125); and 
human epididymis protein 4 (HE4) for monitoring of ovarian cancer; a-fetoprotein 
(AFP) for staging of non-seminomatous testicular cancer and monitoring of 
hepatocellular carcinoma; prostate specific antigen (PSA) for screening and 
monitoring of prostate cancer, thyroglobulin (Tg) for monitoring of thyroid 
cancer; carcinogenic embryonic antigen (CEA) for monitoring of pancreatic 
cancer; and CA15-3/CA27-29 and HER2/neu for monitoring of breast cancer 
[14]. Other approved protein biomarkers are identified in urine, such as nuclear 
matrix protein 22, fibrin-/fibrinogen-degradation products, and bladder-tumor 
antigen for the monitoring of bladder cancer, or by immunohistochemistry using 
tumor tissues, such as the estrogen receptor for breast cancer [14]. Additional 
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approved cancer biomarkers are DNA based, such as human epidermal growth 
factor receptor 2, or HER2/neu, for breast cancer [14]. 
1.4 Microheterogeneity: The unheard noise  
Protein structure plays an important role in its function. Even slight modifications 
in amino acid sequence or changes in small molecules attached to the main 
sequence due to post translational modifications can result in several forms of a 
protein which can be functionally very distinct. These alterations thus may have 
important role to play in disease physiology. Defining and quantifying these 
events is therefore critical to understanding the pathobiological mechanisms 
underlying disease. Currently, protein microheterogeneity within the general 
population which is not distinguishable, simply adds biological “noise” in 
conventional assays and sometimes contributes to misleading data. If these 
different forms can be distinctly seen then the knowledge of their qualitative 
differences, their relative abundances, and their frequency within distinct 
populations will markedly advance our understanding of the pathobiological 
mechanisms underlying disease and significantly improve our chances of finding 
clinically useful biomarkers. Unfortunately, due to speed and simultaneous 
analysis of all proteins being the priorities in earlier proteomics research, not 
much attention has been paid to the fine structure of proteins (microheterogeneity) 
which has the potential to completely alter protein activity. Thus, defining protein 
microheterogeneity in sizable populations of healthy and diseased subjects is of 
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great importance in order to better understand disease physiology specially in case 
of cancer. In order to establish a protein biomarker, high throughput techniques 
are required that are precise, cost effective and sensitive. For this purpose 
currently used techniques have their limitations as far as studying protein’s 
microheterogeneity is concerned. Immunological assays such as enzyme linked 
immunosorbent assay (ELISA) have been used to study protein concentrations in 
biological samples. But, these assays only provide us information regarding the 
quantitative amount of the total protein in the sample. This brings us to a blind 
spot in the analysis because multiple modifications (arising from genetic 
diversity, transcriptional and post-translational events) leading to protein diversity 
(microheterogeneity) in the human population (Figure 2) remain indistinguishable 
from each other. In global proteomics, proteins are fragmented. Few of these 
Figure 2: Illustration of real qualitative variation that exists within what is 
considered to be one protein using common immunoassays. MSIA enables us to 
look at the real picture where a protein exists in several different forms. This 
information about the heterogeneous structures opens up an unexplored space 
where potential biomarkers may exist. 
9 
 
 
proteolytic fragments are then identified using mass spectrometry. The results are 
then mappd to a parental protein using database search engines. But in this 
approach, critical information about the native protein is irrecoverably lost 
because the approach assumes that one or a few proteolytic fragments 
unambiguously define a single precursor which may not be true considering 
protein microheterogeneity. It is only when all the variants in their intact forms 
are separately isolated and characterized with total sequence coverage that this 
diversity is evident and can be correctly assigned. With immunological methods, 
each variant requires its own highly specific antibody system (usually two) to 
yield an accurate evaluation of its contribution to the entire cluster. For the 
plethora of human proteins identified, only a handful of such immunoassays 
currently exist. Consequently, human protein heterogeneity is imperceptible by 
these techniques.  
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Chapter 2 
MASS SPCETROMETRIC IMMUNO ASSAY 
2.1 Technique  
Mass Spectrometric Immunoassay (MSIA) invented by my advisor Dr. Nelson is 
a rational combination of micro-scale immunoaffinity capture and mass 
spectrometry [15]. In MSIA intact proteins are captured using specific antibodies 
as is done in traditional immunoassays. But, the advantageous strategy used in 
case of MSIA is that instead of immobilizing antibodies on a flat surface or beads 
the antibodies for protein or peptide capture are immobilized in small, porous 
microcolumns that are fitted at the entrance of a pipettor tip (Figure 3). These tips 
are termed affinity pipettes. Immobilizing of antibodies onto these pipettor fitted 
microcolumns allows for higher efficiency of protein capture because the sample 
can readily be aspired and dispensed (multiple times) through the tip to expose the 
immobilized antibody to the antigen present in the sample. Typically a sample is 
pipetted for about 1500 times with the use of pipettor robot. Once the pipetting is 
over the antibodies have the antigen in all the different variant forms available in 
the sample captured for analysis. Along with the protein of interest some other 
sample components and salts are also nonspecifically retained. These 
nonspecifically retained components are removed by rinsing the tip with 
appropriate buffer and water. 
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The protein of interest with all its captured variants is now ready for analysis 
using any suitable mass-spectrometric (MS) platform. The platform of choice 
depends on the target of interest which could be a full length protein or a peptide 
fragment. The size of the target and abundance in the sample also dictates the 
choice for a suitable MS platform. Then of course the availability and ease of use 
of the instrument plays a role in choosing the MS platform especially during the 
development of a qualitative MSIA. Next step after the buffer wash of the pipettor 
Figure 3: Diagram of the MSIA process. A biological sample is repetitively 
passed through the MSIA-Tip, performing immunoaffinity capture of the targeted 
protein. While nonspecific components within the biological fluid are rinsed 
away, the concentrated target analyte is eluted for analysis by either MALDI or 
ESI-based mass spectrometry. Mass spectral peak areas are then integrated to 
determine the relative percent abundance of each unique variant that, in the 
conventional vernacular, together constitute (nominally) “one” protein. 
12 
 
 
tip depends on the chosen MS platform. During the course of work presented in 
this thesis I have worked with two platforms viz Matrix Assisted Laser 
Desorption Ionization (MALDI)-MS and electrospray ionization (ESI-MS). For 
MALDI based analyses, a small volume of MALDI matrix is aspirated into the 
affinity pipette, and the antigen-containing eluate is quickly deposited directly 
onto a MALDI target for ensuing MS analysis. For ESI based configurations, an 
acidic buffer is used and the eluate is deposited onto titer plates for downstream 
MS analysis. 
2.2 Advantages 
MISA offers several advantages over conventional techniques of protein analysis. 
Firstly, MSIA avoids protein fragmentation and enables us to capture intact 
proteins using affinity chromatography and analyze its complete structure using 
mass spectrometry. This unique feature of MSIA allows us to examin structural 
microheterogeneity of target proteins in different physiological conditions. 
Secondly, it offers the possibility of simultaneous capture and analysis of multiple 
proteins in the same sample. This can be done by immobilizing multiple 
antibodies in the same affinity pipette (i.e. multiplexing) as long as the antibody 
affinities and protein concentrations in the sample are not several orders of 
magnitude different, and also the masses of the proteins to be analyzed are 
relatively distinct so that their signals do not overlap in the mass spectra.After the 
capture of multiple proteins the following MS analysis results in a mass spectrum 
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that contains distinct signals from all proteins. Multiplexing is of great clinical 
significance in scenarios were one protein biomarker is not sufficient to provide 
information that can be clinically useful and needs a range of proteins to be 
analyzed. Also for screening purposes multiplexing is very helpful. This reduces 
both the cost and time associated with large population screenings. Thirdly, MSIA 
is high throughput. Samples are prepared onto a 96 well titer plate in parallel for 
the affinity capture. The eluates are then deposited onto 96 well formatted 
MALDI targets or titer plates for ESI. This entire process of affinity capture and 
elution of the target onto the MS platform after the assay development is fully 
automated and can be carried out in less than an hour, which means less than a 
minute for one sample to be extracted and eluted for analysis. Given this 
capability of high throughput analysis population studies of some biomarkers on a 
large scale involving thousands of samples have been performed [16]. Fourthly, 
MSIA can accommodate a range of sample volumes from as small as 10 μl to as 
large as 50 ml. The advantage comes from the process of repeated sample rinsing 
through the pipette until enough antigens are bound to the antibody. Given all 
these advantages of MSIA technique over conventional immunoassays it has been 
used to study a wide range of proteins with concentrations ranging from ~ 10 
pg/ml to ~ 50 mg/ml [14] and promises to be a useful tool to study human plasma 
proteome which spans a wide dynamic range. 
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Chapter 3 
PROTEINS OF INTEREST 
 
In order to develop assays for cancer associated biomarkers we need to choose the 
candidate proteins. This choice is made by mining into research article/abstract 
database provided by PubMed and prioritizing the candidates based on their 
relevance to the disease of interest. This thesis includes work on development of 
assays for three different proteins viz. Insulin like growth factor-1 (IGF-1), 
Hemopexin and Tetranectin.  
3.1 IGF-1 
IGF-1 is a member of insulin growth factors (IGF-1 and IGF-2). It is produced 
mainly by the liver but is also produced in several other tissues [17]. The levels of 
IGF-1 in tissues and serum are variable and are regulated ontogenically as well as 
by multiple hormones and nutritional factors. Growth hormone is the most 
prominent stimulus for IGF-1 production. Normal IGF-1 levels in plasma range 
from 20-600 μg/L [18]. IGF-I levels in human fetal serum are relatively low, 
growth hormone-independent, and are positively correlated with gestational age 
and birth weight. During childhood IGF-1 concentrations in serum shows a slow 
and gradual rise and during puberty, IGF-I concentrations rise to 2–3 times above 
the levels found in adults which is related to the action of sex steroids. In 
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adulthood, serum IGF-I levels show a gradual and progressive age-associated 
decline [19]. As the name suggests these are involved in regulation of cell 
proliferation, differentiation and apoptosis. 
3.1.1 Structure: 
 IGF-1 is a single polypeptide composed of 70 amino acids, with a calculated 
molecular weight of 7649 Da. It has three intramolecular disulfide bridges as 
shown in Figure 4 [20] These disulfide bridges between cysteine residues 6-48, 
18-61 and 47-52 help to determine the shape of the protein by playing  
 
important role in its folding and also play important role in its function. Without 
any of the disulfide bridges, significant decrease in its binding to its receptor is 
observed which indicates that IGF conformation undergoes change and its activity 
is suppressed if these disulfide bonds are disrupted [2]. IGF-1 as the name 
Figure 4: Sequence of human IGF-1. Disulfide bonds are indicated by solid lines 
[2]. 
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suggests is insulin like in its structure. About 50% sequence similarity exists 
between insulin and IGFs. IGF molecules have four domains which are 
designated as A, B, C, and D (Figure 5). Domains A and B are homologous with 
the A and B chains of insulin, respectively. Even with this high degree of 
similarity many difference exist in their functions.  
 
3.1.2 Functions: 
The functions of IGFs are mediated through their interaction with two 
transmembrane receptors (IGFR-1 and IGFR-2). The type 1 IGF receptor 
mediates many diverse and tissue specific IGF actions on all cell types. In 
general, it is believed that all of the effects of IGF receptor activation are 
mediated by tyrosine kinase activation and phosphorylation of substrates, which 
Figure 5: Tertiary structure of IGF-1 [1]. 
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activate specific cellular pathways leading to various biological actions. Among 
these effects are induction of cell growth, maintenance of cell survival (prevention 
of apoptosis) and induction of cellular differentiation [21]. The type 2 IGF-
receptor bears no structural homology with the type 1 IGF receptor and binds both 
IGF-II and Mannose-6-P-containing lysosomal enzymes, as well as retinoic acid, 
while IGF-I binds to it with substantially lower affinity [22]. This receptor acts as 
a growth inhibitory component of the IGF system, responding to and mediating 
multiple anti-mitogenic systems.  
In plasma, IGF-1 is complexed with a family of proteins called IGF binding 
proteins (IGFBPs). About 99% of the IGFs circulate in the serum in the form of 
complex with IGFBPs and less than 1% only is available in the free unassociated 
form. The complex increases the half-life of IGF-1 in the plasma, help in 
transportation of IGF-1 to target cells and play a role in the interaction of the IGF-
1 with its surface membrane receptors [23]. These IGFBPs are six distinct 
proteins termed IGFBP-I through IGFBP-6 having high binding affinity to IGF-1. 
IGFBP-3 is the major IGFBP in normal human plasma and circulates in adult 
plasma as part of a ternary complex; consisting of IGFBP-3, an IGF peptide, and 
an acid-labile subunit [24] IGFBPs both inhibit and enhance the action of IGF-1. 
Inhibition presumably is caused because of IGFBPs competing with IGF receptors 
for IGF peptides[25] while several of the IGFBPs enhance IGF action, by 
facilitating IGF delivery to target receptors.[26] IGFBPs in themselves are also 
bioactive and have a variety of IGF independent functions. These include growth 
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inhibition, direct induction of apoptosis, and modulation of the effects of other 
non-IGF growth factors. These effects of IGFBPs are mediated by binding to their 
own receptors. IGF action which is regulated by IGFBPs is indirectly modulated 
by IGFBP proteases, which have capability of IGFBP degradation[24] and 
demonstrates clear growth hormone dependence.  
3.1.3 Clinical significance: 
Clinical significance of IGF-1 is considerable. Apart from several carcinomas it 
has been associated with a number of other diseases including cardiovascular 
diseases (myocardial infarction (MI), heart failure) [27], acromegaly and diabetes 
[27].  
Clinical studies of IGF-I in patients with type 2 diabetes has shown improvement 
in their insulin sensitivity [28] In type 1 diabetes, multiple clinical studies have 
shown improved glycemic control and decreased insulin requirement through 
IGF-I therapy[29] Apart from this, studies on several animal models have proved 
the role of IGF-1 in carbohydrate metabolism [30][31].  
In relation to cardiovascular diseases, studies have shown a negative correlation 
between IGF-1 and total HDL-cholesterol ratio and IGF-1: IGFPB-3 molar ratio 
has also been inversely correlated with total HDL-cholesterol ratio and 
triglycerides [32]. IGF-1 meditated beta cell proliferation is found to be inhibited 
by free fatty acids suggesting direct link between obesity, IGF-1 and glucose 
regulation [33]. Several studies have associated low total or free IGF-1 levels with 
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an increased risk for cardiovascular disease. In particular, low IGF-1 levels have 
been correlated with increased risk of MI, angina and ischemic stroke [34] [35] 
[36]. 
IGF-1 has also been associated with different cancer types including prostate [37], 
colon[38] [39]
,
 [40], lung[41]
,
 [42] and premenopausal breast cancers [43]
,
 [44]. 
Specially, in the case of prostate cancer several epidemiological studies conducted 
in distinct populations have demonstrated that elevated serum IGF-I level is 
associated with an increased risk of prostate cancer[45]
,
 [46]. The risk of cancer is 
higher among people with raised concentrations of IGF-I, and it is lower among 
those with high concentrations of IGFBP-3 which is the main binding protein 
complexed with IGF-1. In many studies anthropometric markers of the activity of 
insulin-like growth factor-I, such as height and leg length, are associated with 
cancer incidence, particularly with the cancers for which risk increases with rising 
concentrations of IGF-1. [47]    
 3.2 Hemopexin: 
Hemopexin is a plasma glycoprotein with a high affinity of binding to heme (Kd < 
1 pM) at an equimolar ratio.[40] It transports heme to hepatocytes for salvage of 
the iron. It is mainly expressed in liver as an acute protein which is expressed as a 
result of an inflammatory event. [41]   
3.2.1 Structure: 
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Human hemopexin is composed of a single polypeptide chain containing 439 
amino acid residues. It has six intrachain disulfide bridges. The molecular weight 
of hemopexin as calculated from the amino acid sequence of the unmodified 
polypeptide chain is 49, 295 Da. This molecular weight is much less that what has 
been reported in the literature which ranges from 57,000 Da to 80,000 Da.[48], 
[49] The extra mass observed comes from additional modifications of the protein. 
The amino-terminal threonine residue has an O-linked galactosamine 
oligosaccharide, and the protein has five N-linked glycans attached to the acceptor 
sequence Asn-X-Ser/Thr (X represents any amino acid) and also binds heme. This 
increases the overall mass of hemopexin. Hemopexin exhibits internal homology 
in amino acid sequence. Figure 6 shows that hemopexin exhibits internal 
duplication. Hemopexin comprises of two homologous domains of about 200 
residues each, joined by a 20-residue linker.  
Figure 6: Internal homology of human hemopexin. Residues that appear in 
equivalent positions in each segment of the protein are enclosed in solid boxes. 
Gaps have been inserted to maximize the homology. Conserved cysteines and 
tryptophans are shaded, and the disulphide bonds are shown. The attachment 
sites for galactosamine and glucosamine oligosaccharides are indicated by . and 
* respectively [4]. 
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Crystal structure of isolated hemopexin C-terminal domain shows that it has a 
unique four-bladed β-propeller fold which is similar to those found in many other 
proteins like collagenases, clathrin and integrins. [50] Such domains are of 
importance in many biological processes especially as mediators of protein-
protein interaction. [51] The N-terminal and C-terminal domains (residues 1–208 
and 228–435) both have the same four bladed β-propeller fold, resembling two 
disks that lock together at a 90°angle, with the face of the N-domain packing 
against one edge of the C-domain. The connecting loop between the two domains 
provides structural features that form the heme binding site and mediate domain 
association. This linker plays a critical part in creation of the binding site, forming 
its outer boundary and interacting with the heme to help stabilize the complex. 
Figure 7: Structure of the heme–hemopexin complex. (a) and (b) are orthogonal 
views. The β-propeller domains are colored blue (N-domain) and red (C-domain), 
the heme group green, coordinating histidine residues cyan and disulfide bonds 
yellow [3]. 
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The linker has no significant secondary structure and its conformation is 
determined by the way it wraps around the heme. Two histidines coordinate the 
heme iron: His213, from the linker peptide, and His 266, from a loop of the C-
terminal domain, giving a stable bis-histidyl Fe(III) complex, with planar heme 
and regular geometry Figure 7 shows the heme-hemopexin complex.  
3.2.2 Functions: 
Turnover of heme proteins, like hemoglobin, results in release of heme into 
extracellular fluids. Free heme has severe consequences for health because free 
heme is a major source of iron for invading bacterial pathogens and is highly toxic 
because of its ability to catalyze free radical formation. Heme mediated oxidative 
stress thus contributes to aging and various pathological states, including stroke 
and Alzheimer’s disease.[52] Protection against free heme is provided by 
hemopexin. The high affinity of hemopexin for heme (Kd < 1pM) and the 
presence of specific receptors for the heme–hemopexin complex on hepatocytes 
and other cell types make hemopexin a candidate for the transport of heme to 
specific sites of catabolism. Once bound to hemopexin, heme is only released 
upon interaction with a specific surface receptor on liver cells where hemopexin is 
internalized by receptor mediated endocytosis. Internalization of heme–
hemopexin complex further stimulates intracellular protective mechanisms, 
including the induction of heme oxygenase (HO), and other signaling pathways. 
Heme is catabolized by HO that opens the porphyrin ring producing biliverdin 
and carbon monoxide, and releasing iron that can be bound by ferritin. Ferritin is 
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the major intracellular depot of non metabolic iron. It is a multimeric protein 
composed of 24 subunits of two types (heavy chain and light chain), and has a 
very high capacity for storing iron (up to 4500 mol of iron per mol of ferritin). 
Together, HO and ferritin allow rapid shifting of iron from heme into the ferritin 
core where iron is less available to catalyze deleterious reactions. Thus heme 
binding and transport by hemopexin provides extracellular and intracellular 
protection against free heme oxidative damage, limits access by pathogens to 
heme and conserves iron by recycling the heme iron.[53] 
3.2.3. Clinical significance: 
In adults, serum hemopexin concentration range between 0.40-1.50 
g/l. Hemopexin is synthesized in the fetus and the serum concentrations in 
newborn babies are ∼20% of the adult values and start rising immediately after 
birth.[54] 
Changes in hemopexin concentration have been correlated with many clinical 
conditions. Following intravascular hemolysis, free hemoglobin is complexed by 
circulating hemopexin which has a hemoglobin binding capacity between 0.7-1 
g/l depending on the phenotype[55]  Plasma hemopexin concentrations decrease 
in chronic or severe hemolysis. Mechanical trauma resulting from physical 
training and long distance jogging may also lead to enough hemolysis to deplete 
circulating hemopexin even in trained athletes. Lower serum concentrations of 
hemopexin during pregnancy and with menopause have been reported 
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in conditions of pre-eclampsia [56]
,
 [57] and in postmenopausal women treated 
with estrogens.[58] In the absence of hemolysis, 
decreased hemopexin concentrations are observed in chronic liver diseases due to 
decrease in synthesis of the protein [59], in active porphyria cutanea tarda due to 
massive overproduction of porphyrins [60], and in severe malabsorption. 
Low hemopexin concentrations can also be found in hemorrhagic 
pancreatitis which is attributable to the breakdown of erythrocytes in 
the peritoneal cavity followed by the release of hemin into the circulation.[54] 
Hemopexin is a glycoprotein. Glycoproteins have been shown to correlate with 
progression of several cancers including prostate cancer [61], colorectal cancer 
[62], and breast cancer. [63] Hemopexin also has been shown to change in its 
structure specially glycosylation in several cancers. Glycosylation changes also 
correlate with liver diseases, so serum glycoprotein such as hemopexin promises 
to be a potential biomarker of hepatocellular carcinoma (HCC) which often 
develops on the background of cirrhotic liver. Studies have shown that branching 
α-1,3-fucosylated multiantennary glycans on hemopexin were increased in case of 
HCC patients when compared to another group of cirrhosis patients without HCC, 
fibrosis patients and healthy individuals. [64] In case of pancreatic cancer it was 
shown that both sialylation and fucosylation increased specifically in case of 
cancer patients compared to patients with chronic pancreatitis without cancer and 
healthy individuals. [65] Glycosylation changes in tumor-secreted proteins may 
also reflect fundamental changes in enzyme levels (or enzyme activities) involved 
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in the glycosylation pathway. Thus, study of hemopexin glycosylation variation 
may also lead to the identification of disease associated glycan alterations and 
new diagnostic markers in pancreatic cancer as well as in other types of cancer. 
3.3 Tetranectin: 
Tetranectin (TN) is a plasminogen binding protein which binds specifically to its 
kringle 4 domain (Kd = 0.5μM). [66] It also interacts with sulfated 
polysaccharides, fibrin and apolipoproteins. [67]
,
 [68]
,
 [69] Tetranectin is found is 
a many tissue types in human body. It was first isolated from human plasma, and 
is abundant in various cell types including monocytes, neutrophils, fibroblasts and 
osteoblasts. It is also found in the extracellular matrix of several carcinomas.[70] 
3.3.1 Structure:  
Human TN is a homotrimeric protein. Each of the monomer polypeptide chains 
consist of 181 amino acid residues. Three disulfide bonds connect Cys-50 to Cys -
60, Cys-77 to Cys-176, and Cys-152 to Cys-168. Each monomer of TN consists 
of a carbohydrate recognition domain (CRD) (residues 50-181) connected to a 
long alpha helix. Each monomer has two distinct regions, one consists of six β-
strands and two α-helices and the other region is composed of four loops having 
two calcium ions. The calcium ion at site 1 forms an eight fold coordinated 
complex and has Asp 116, Gluc 120, Gly147, Glu150, Asn151, and one water 
molecule as ligands. The calcium ion at site 2 is believed to be involved in 
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recognition and binding of oligosaccharides. This calcium ion forms a seven fold 
coordinated complex with Gln143, Asp145, Glu150, Asp165, and two water 
molecules as ligands. [5] The overall structure of a TN monomer is shown in 
Figure 8. Sequence homology studies and TN’s calcium dependent binding to 
specific sugars, which is also a feature of a class of proteins called C-type 
(calcium dependent) lectins, groups it into the same class. Other C-type lectins 
include pancreatic stone protein, sea raven antifreeze protein and snake venom 
botrocetin.   
3.3.2 Function: 
Researchers have been studying tetranectin over years and these studies have led 
to our understanding of its amino-acid sequence, 3-D structure and corresponding 
gene sequence, characterization of its CRD, interaction with certain 
macromolecules and its expression in different cells and tissues but still its exact 
physiological role is not elucidated. TN resembles mannose binding proteins 
(MBP) from rat serum and also human MBP in its trimeric structure. As shown in 
Figure 8, the monomer is characterized by a long α-helix which forms the neck 
region. Trimerization of TN and these MBPs are formed with coiling of the α-
helical coils of the monomers forming an α-helical coiled coil. The orientation of 
the CRDs with respect to the coiled coil stem determines the spatial separation of 
the carbohydrate-binding sites. This spatial separation differs in different proteins 
with CRD and holds importance in determining the specificity of the proteins. 
Since TN has a CRD that binds specific carbohydrates and also has a domain 
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within residues 1-49 which is responsible for its binding to kirngle 4 domian of 
plasminogen, one of its functions is to target plasminogen to specific carbohydrate 
 
 
ligands on cell surfaces in extracellular matrix or to fibrin. The fact that TN is a 
part of fibrinolytic system and also found abundantly in plasma and in various 
Figure 8: Overall structure of TN monomer. Two portions consisting of a long α-
helix (represented as E2) and a carbohydrate binding domain (represented as 
CRD) are shown. The two calcium ions are shown as yellow spheres. The three 
disulfide bonds between residues 50-60, 77-176 and 152-168 are shown by ball 
and stick representation and labled 1, 2,3 [5]. 
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tissues implies that it serves an important functional role in fundamental 
biological processes like tissue degradation, cell migration, and the spreads of 
cancer by metastasis and invasion. TN may also play an important role in 
mineralization during osteogenesis. [71]  
3.3.3 Clinical Significance 
Plasma level of tetranectin in health adults is ~100 nM. [72] This concentration 
has been found to change in case of various carcinomas. [73] TN levels have been 
found to decrease in case of ovarian cancer [74], colonic cancer [75] and also in 
rheumatoid arthritis. [76] TN is also present in stroma of various cancers 
including breast, colon and ovary whereas it is absent in the normal non cancerous 
tissues. [77] TN is also found to distribute along with plasminogen in a similar 
fashion at the invasive front of the cutaneous melanoma lesions. [78] Though the 
mechanism of how TN affects cancer progression is not very clear these are 
enough evidence to show it being an important protein which may be more 
generally associated with a variety of cancers. 
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Chapter 4 
EXPERIMENTAL METHODS 
4.1 Affinity tip preparation:  
Pipette tips with carboxylic acid functionalized porous glass frits were ordered 
from Intrinsic Bioprobes. Inc. The obtained tips were treated with 0.2M 
hydrochloric acid to remove sodium/potassium salts and generate free carboxyl 
groups. Subsequently the tips were washed thoroughly with acetone and vacuum 
dried. The dried tips were activated with CDI (1,1’- Carbonyldiimidazole) by 
repeated rinse with 50g/l solution of CDI in 1-methyl-2-pyrrolidinone (NMP) for 
approximately 45min with the aid of a Beckman Multimek 96 channel automated 
pipettor robot.  After CDI activation, affinity tips were blotted to remove excess 
NMP followed by two NMP rinses and blotting to remove excess CDI.  
For IGF-1 analysis, these CDI activated tips were then coupled with rabbit 
monoclonal IGF-1 antibody (0.25mg/ml) obtained from R&D systems 
(Catalogue# MAB291) in MES buffered saline, pH 4.7 by repeated rinsing for a 
total exposure time of 50min with the help of pipettor robot.  
For Hemopexin analysis, the CDI activated tips were coupled with Goat anti-
Human Hemopexin antibody from Mybiosource, LLC (Catalogue# MBS686023) 
diluted in MES buffered saline to a final concentration of 0.05mg/ml, pH 4.7 by 
30 
 
 
repeated rinsing for a total exposure time of 50 min with the help of pipettor 
robot.  
For Tetranectin analysis, the CDI activated tips were coupled with mouse anti-
Tetranectin antibody from Thermo Scientific (Catalogue# 5B7) diluted in MES 
buffered saline to a final concentration of 0.05mg/ml, pH 4.7 by repeated rinsing 
for a total exposure time of 50 min with the help of pipettor robot.  
After antibody coupling the affinity tips were rinsed with 1M ethanolamine pH 
8.5 to block any vacant CDI-preactivated sites followed by two rinses with 10mM 
HBS-N. Affinity tips were then stored at 4
0
C to be used within 3 months time. 
4.2 Mass Spectrometric Immunoassay: 
4.2.1 IGF-1:  
Prior to extraction, 60μl of HEPES buffered saline (HBS-EP) and 60μl of 0.5% 
SDS (w/v) were added to 40μl plasma followed by 10 minutes of incubation at 
32°C. After incubation an additional 840μl of HBS-EP was added to the solution 
for a total analytical volume of 1 ml. IGF-1 extraction was done with the aid of 
Beckman Multimek robot by repeatedly (50 repetitions) drawing and expelling 
(back into the analytical volume) 200μl aliquots of the analytical volume through 
an anti-IGF affinity pipette tip. After extraction, pipette tip was rinsed in the 
respective order using HBS-EP, H2O, Tris HCl (100mM, pH 4.6), H2O, 
acetonitrile:water (20:80; v/v), H2O. Each rinse was accompanied with 5 
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repetitions of 200μl. Then the pipette tip was vacuum dried at room temperature 
and IGF-1 was eluted by drawing 4μl of MALDI matrix (saturated aqueous 
solution of α-cyano-4-hydroxycinnamic acid (ACCA), in 33% (v/v) acetonitrile, 
0.45% (v/v) Trifluoroacetic acid (TFA) into the pipette and depositing on to the 
MALDI target.  
The target plate was inserted in Bruker autoflex instrument for MALDI-TOF MS 
operating in the positive ion, delayed extraction mode; linear mode with ‘ion 
source 1’ at 20KV, ‘ion source 2’ at 18.5KV, lens at 7.00KV, 100ns after laser 
pulse delay extraction, deflection signal suppression up to m/z 2000. Eight 
thousand laser shots were signal averaged for each mass spectrum. Spectra was 
calibrated with mixture of 4 proteins supplied by Bruker (Cat No: 208241) which 
consisted of, in average mass, m/z 5743.52 (Insulin [M+H]
+
), 6181.05 
(Cytochrome-C [M+2H]
2+
), 8565.76 (Ubiquitin-I [M+H]
+
), and 12360.97 
(Cytochrome-C [M+H]
+
). Individual mass spectra were baseline subtracted and 
smoothed.  
4.2.2 Hemopexin: 
 One hundred microliters of human plasma was mixed with 100μl of HEPES 
buffered saline (HBS-N) and Hemopexin was extracted by repeatedly (50 
repetitions) drawing and expelling (back into the analytical volume) 80μl aliquots 
of the analytical volume through an anti-Hemopexin pipette tip. HBS-N, H2O, 2M 
ammonium acetate:acetonitrile (3:1), H2O rinse (in this order, each rinse was 10 
32 
 
 
repetition of 150μl) was followed by the extraction. After which the Hemopexin 
was eluted with the assistance of MALDI matrix (saturated aqueous of sinapinic 
acid, in 33% (v/v) acetonitrile, 0.45% (v/v) Trifluoroacetic acid (TFA)) on the 
MALDI target. The samples were analyzed with MALDI-TOF MS. The best 
obtained results were further analyzed with ESI-TOF MS.   
ESI-TOF MS analysis: After hemopexin extraction and rinsing of the tip, elution 
was accomplished by air drying of the pipette and then 5µl of a mixture 
containing 0.4% Triflouroacetic acid in water and acetonitrile solution (90:10 v/v) 
was drawn and mixed over the pipette affinity capture frit for 30 sec and then 
dispensed into a 96-conical well polypropylene autosampler tray. Eluted sample 
was injected into the LC-TOF-MS within 10 min of elution. 
Samples were injected by a Spark Holland Endurance autosampler in a microliter 
pick up mode and loaded by an Eksigent nano LC*1D at 10µl/min (90/10 
water/acetonitrile containing 0.1% formic acid , solvent A) onto a protein captrap. 
After 2 min, the divert valve position was automatically toggled and flow over the 
cartridge changed to 1µl/min solvent thus running directly to ESI inlet. Over 5min 
the solvent gradient was ramped from 10% acetonitrile to 90% acetonitrile to 
elute the intact protein into the mass spectrometer. 
4.2.3 Tetranectin 
Forty microliters human plasma sample was incubated with 120μl of HEPES 
buffered saline (HBS-EP) containing 0.2% SDS and 10mM NOG  for 15 minutes 
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at 36°C. After this incubation HBS-EP was added to the sample for a total 
analytical volume of 1ml. Tetranectin was extracted from the diluted sample with 
the aid of  Beckman Multimek robot by repeatedly (50 repetitions) drawing and 
expelling (back into the analytical volume) 200μl aliquots through an anti-
tetranectin affinity pipette tip. The affinity tip loaded with the protein was then 
rinsed in sequence with HBS-EP and water using 200μl each time for ten 
repetitions. MALDI matrix (saturated aqueous solution of sinapinic acid, in 33% 
(v/v) acetonitrile, 0.45% (v/v) Trifluoroacetic acid (TFA)) was used for the elution 
of tetranectin on to the MALDI target. 
The target plate was inserted in Bruker ultraflex instrument for MALDI-TOF-MS 
operating in positive ion, delayed extraction mode; linear mode with ‘ion source 
1’ at 25KV, ‘ion source 2’ at 23.5KV, lens at 9.00KV, 90ns after laser pulse delay 
extraction, deflection signal suppression up to m/z 4000. Ten thousand laser shots 
were signal averaged for each mass spectrum. Spectrum was calibrated with 
mixture of eight proteins supplied by Bruker. Individual mass spectra were 
baseline subtracted and smoothed. 
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Chapter 5 
RESULTS AND DISCUSSIONS 
5.1 MSIA development for IGF-1:  
IGF-1 associates with IGF binding proteins and circulates in the plasma in the 
form of a complex. One of the challenges in developing assay for IGF-1 is to be 
able to disrupt the complex and extract IGF-1. SDS was used to disrupt this 
complex at a concentration 0.2% which was further diluted to 0.03% so as not to 
interfere with the extraction of the IGFs. Figure 9A shows the mass spectra where 
the IGF complex was not disrupted. It was obtained with a plasma sample diluted 
with HBS-EP and untreated with SDS. In Figure 9B the spectra is obtained from a 
Figure 9: Result of IGF-IGFBP complex disruption. (A) MSIA analysis spectra of 
HBS-EP diluted plasma samples without any complex disruption. (B)  Spectra 
obtained after SDS treatment of the plasma sample for complex disruption. 
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sample treated with SDS to break the IGF complex.  
The untreated sample does not show any peaks corresponding to IGF. In the SDS 
treated sample various peaks are visible. Peaks at m/z = 7648.4 and 7470.2 
correspond to IGF-1 and IGF-2 respectively. The peak obtained at m/z = 7401.2 
corresponds to a variant of IGF-2 (des(Ala)-IGF-2). The calculated molecular 
weights of these proteins are 7648.7, 7469.4 and 7398.3 respectively. The peak 
observed at m/z = 6633.9 is nonspecifically retained apolipoprotein protein C-1. 
In order to remove non-specifically retained protein, the affinity tip was rinsed 
with a detergent solution consisting of 4.5% Tween 20, 150mM Octyl-β-
pyranoside, 1.5M ammonium acetate in 10x concentrated PBS. Though this rinse 
removes nonspecifically retained apolipoprotein C-1 as seen in Figure 10, it 
increases the noise level in the spectra which diminishes the overall quality. So, it 
was decided not to incubate the plasma sample with the detergent mixture along 
Figure 10: MSIA spectra obtained after 
detergent rinse of the affinity tip 
following extraction. 
Figure 11: MSIA analysis spectra 
obtained after TRIS-HCl rinse of the 
affinity tip after protein capture. 
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with SDS and rather use Tris-HCl buffer as a rinsing agent to improve the spectra 
and explore the possibility of removing the nonspecific binding. Figure 11 shows 
the spectrum obtained after Tris-HCl rinse of detergent incubated sample 
extraction. Though nonspecifically retained apolipo-protein is still present the 
signal to noise ratio of the spectrum is considerably improved and a peak at m/z = 
7061.6 corresponding to another apolipoprotein C-1’ is visible.  
This MSIA for IGF-1 was used to analyze sample from type 2 diabetic (T2D) 
patients in hope of being able to observe any variants of the protein. The sample 
that was used clearly showed bifurcation of the the IGF-1 peak at m/z 7648 
(Figure 12). The mass difference between the bifurcated peaks is 16Da which is 
attributed to oxidation of methionine residue as it forms methionine sulfoxide 
with additional oxygen in the molecule. Though this result is not a conclusive 
evidence which can attribute methionine oxidation to T2D but it clearly 
Figure 12: Analysis of type 2 diabetic (T2D) sample. (A) MSIA analysis spectra 
of healthy sample showing the peak corresponding to IGF-1. (B)  Spectra 
obtained from T2D sample analysis which show a split peak of IGF-1 indicating 
oxidation of methionine residue. 
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demonstrates that usefulness of the present MSIA developed in capturing 
variations in the protein structure and promises to be useful in analysis of large 
cohorts for statistically meaningful studies.  
5.2 Development of a MSIA for Hemopexin:  
Conventional MALDI-TOF-MS lacks in its capability to resolve smaller but 
biologically meaningful mass shifts at m/z ratios greater than about 30,000. 
Hemopexin is 60kDa in size which is beyond this optimal range for analysis by 
MALDI. Electrospray ionization (ESI) is the preferred platform as it increases the 
charge state of intact proteins and provides higher resolution. In order to analyze 
samples by ESI-TOF-MS the primary assay was first developed on MALDI 
platform because of its ease of use and accessibility. The initial assay was 
optimized for plasma dilution and antibody concentration. One hundred micro-
liters of plasma diluted in 300μL of HBS-N buffer was extracted with an affinity 
tip incubated in 0.1g/L of anti-Hemopexin antibody and rinsed in order with 
HBS-N, water, a 3:1 2 M ammonium acetate to acetonitrile mixture, then 
waterFigure 13 shows the MALDI-TOF spectrum obtained from this initial assay. 
A peak at m/z = 60441 corresponding to hemopexin is visible along with peak at 
m/z = 66552 which corresponds to nonspecifically retained serum albumin. 
Several attempts were made to eliminate this nonspecific binding of albumin 
which affects the sensitivity of the assay towards hemopexin. Plasma sample was 
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incubated in the previously reported detergent mix (150mM NOG, 4.5% tween20, 
1.5M ammonium acetate, PBS).. 
 
 
Thus, in a different approach the affinity tips were pre-incubated overnight at 4
0
C 
in 60mM HCl in an effort to remove any non-specific binding. The spectrum 
obtained after this pre-incubation in 60mM HCl with a sample not-treated with 
the detergent did not show any peak for hemopexin. Further, detergent treated 
plasma sample was extracted with HCl pre-incubated tips but was not successful 
in avoiding nonspecifically retained albumin. So it was decided to use the initially 
Figure 13: MSIA spectra obtained from HBS-N diluted plasma sample with anti-
hemopexin antibody. 
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optimize the assay for analysis with ESI-MS.  This was found to be the optimal 
condition to generate a clean spectrum of hemopexin. Samples prepared with 
these conditions were then analyzed by the ESI-MS as shown in Figure 14. The 
ESI-MS spectrum clearly shows different glcosylated forms of the hemopexin. 
 
 
Figure 14: MSIA spectra obtained with ESI-MS platform shows distinct peaks for 
several glycosylated forms of hemopexin. 
 
Table 1: Observed ESI mass spectrum peaks and their interpretations for MSIA 
analysis of Hemopexin 
Measured 
Mass 
(Da) 
Calculated 
Mass (Da) 
Mass 
difference 
(Da) 
Peak 
separation 
(Da) 
Possible 
Modification 
Calculated 
mass 
difference 
(Da) 
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60679 49294 11385  
(HexNac)21, 
(Hex)26, 
(NeuAc)10 
11394.63 
60982  11688 303 + NeuAc 11685.88 
61128  11834 146 
+ 
Deoxyhexose 
11848.02 
61640  12346 512 
+ HexNac 
+NeuAc 
12342.46 
61787  12493 146 
+ 
Deoxyhexose 
12504.60 
5.3 Development of a MSIA for Tetranectin:  
Since tetranectin is a plasminogen binding protein several attempts were made to 
free TN from PLG. Figure 15 shows results from the use of several detergents for 
this purpose. Initially the plasma sample was incubated in 30mM NOG before 
extraction of TN with anti-TN functionalized affinity tip. This however did not 
lead to any detectable peak in the mass spectrum (Figure 15 A). After this, two 
different detergent mixes were prepared Mix1 (150mM NOG, 1.5 M ammonium 
acetate, Concentrated PBS consisting of 0.67 M sodium phosphate and 1M NaCl) 
and Mix2 (150mM NOG, 1.5 M ammonium acetate, PBS and 4.5% Tween) 
successively increasing the detergent strength. After incubation of the sample in 
these detergent mixes and MALDI analysis after subsequent extraction the MSIA 
spectrum as shown in Figure 14 B,C show visible peaks around 20504 Da and 
20795 Da which are reported modified peaks for TN [79]. Further, detergent mix 
3 (HBS-EP with 0.2% SDS and 10mM NOG) was prepare used `for sample 
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incubation followed by subsequent extraction and analysis. The MSIA spectrum 
obtained as shown in Figure 14 D clearly shows four different variations of the 
protein with peaks at m/z 20, 538.79 Da, 20, 825.29 Da, 21, 027.97 Da and 21, 
118.3 Da. These peaks are consistent with variations of TN reported earlier in the 
literature with a new peak at m/z 21, 027.97 which has not been reported before. 
The mass shift in the peaks from the unmodified mass of the protein indicates 
modifications with an oligosaccharide prosthetic group containing terminal sialic 
acid residue. Table 1 summarizes the peaks observed and their possible 
Figure 15: Use of different detergent in order to free TN from PLG. Plasma 
sample was incubated with indicated concentration of the detergent (A) 30mM 
NOG (B) detergent mix 1 (C)  detergent mix 2 (D) 0.25% SDS 
42 
 
 
interpretations.  
Table 2: Observed MALDI mass spectrum peaks and their interpretations for 
MSIA analysis of TN 
Measured 
Mass 
(Da) 
Calculated 
Mass (Da) 
Mass 
difference 
(Da) 
Peak 
separation 
(Da) 
Possible 
Modification 
Calculated 
mass 
difference 
(Da) 
20, 
538.79 
20, 162.8 375.99  
HexNac, 
Hex 
365.33 
20, 
825.29 
 662.49 286.5 + NeuAc 656.58 
21, 
027.97 
 865.17 202.68 + HexNac 859.77 
21, 118.3 
 
 955.5 90.33 
- HexNac, + 
NeuAc 
947.83 
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Chapter 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
In conclusion, mass spectrometric immuno assays for three different proteins have 
been developed. These proteins viz. IGF-1, hemopexin and tetranectin have been 
found in reported literature to show correlations with many diseases along with 
several carcinomas. Though structural characterization of these proteins has 
already been reported but still cohort studies involving large population has not 
been done. To gauge the role of these proteins in diseases these studies hold the 
key. The MSIAs developed during this thesis work provide easy, efficient and 
affordable method for structural characterization of these proteins enabling high 
throughput analysis in large number of samples which is not conveniently doable 
with other protein extraction techniques. Developed assays have shown their 
capability to capture and reveal different structural forms of target proteins 
divulging their structural micro-heterogeneity invisible to commonly used 
immunoassays. With well designed large population studies one or more of these 
structural variants alone or in combinations could be established as biomarkers of 
certain diseases.  
In future these assays will be used to study qualitative variations in structure of 
these proteins in plasma samples from donors with diseases of interest in a small 
cohort of about hundred subjects. Contingent upon promising statistical 
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differences in small cohort study bigger and more diverse cohort study will follow 
with an aim to further characterize the structural variations based in gender, age, 
ethnicity etc. These calcifications will result in better understanding of protein 
diversity in population. Further, quantitative assays will also be developed with 
the help of suitable internal reference standards. Multiplex assay using more than 
one protein involved in same cancer in order to obtain a more robust analysis to 
avoid false positives can also be developed. These assays hopefully will reveal 
some properties either structural or concentration differences which can be 
established and used as biomarkers for disease diagnosis and/or monitoring. 
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